By contrast, antibody‐conjugated MPIO, despite specific binding to their endothelial target VCAM‐1, showed negligible in vivo uptake by tumour macrophages and we propose, therefore, that the use of antibodies rather than peptides as the targeting ligand may represent a preferable route forward for new angiogenesis‐targeted agents. This evidence concerns the gene VCAM1 and neoplasm.